High CV risk in young people is a 'delayed' crisis

Published Date: 08 Mar 2023

Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.

Read Full News

Latest News

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Latest News

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

News All Time

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

New 'heart percentile' calculator helps young adults grasp their long-term risk

A new Northwestern Medicine study introduces a first-of-its-kind online calculator that uses percentiles to help younger adults forecast and understand their risk of a heart event over the next 30 years. With rates of obesity, ...

Potassium-enriched salt recommended for blood pressure control

The use of potassium-enriched salt has now been recommended by the National Hypertension Taskforce—Australia's peak body for blood pressure control—in a new position statement published in the Journal of Hypertension.

Chronic pain may increase risk of high blood pressure in adults

Chronic pain in adults may increase their risk of high blood pressure, and the location and extent of pain and if they also had depression were contributing factors, according to new research published today in Hypertension.

Direct link between peak air pollution and cardiac risk revealed

In Lombardy, the risk of suffering cardiac arrest may increase on days recording high levels of air pollution. This emerges from a study conducted by the Politecnico di Milano and published in the journal Global Challenges.

Hypertension affects the brain much earlier than expected, study suggests

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators. ...

Disrupted calcium signaling can throw the heart off rhythm

A joint study by the University Medical Center Göttingen (UMG) and the University Hospital Würzburg provides new insights into why heart muscle cells lose their rhythm in atrial fibrillation. Disrupted calcium signaling ...

Common gout drug may reduce risk of heart attack and stroke

A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review.

During a heart attack, immediate stenting of other arteries isn't always necessary

A blocked coronary artery causing an acute heart attack must be opened immediately with a stent procedure. However, if other coronary arteries also appear to be narrowed, it is safe to wait and treat those later. This approach ...

New pill cuts 'bad' cholesterol by 60%, potentially replacing injections

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections.

From contraception to menopause: Why women face a higher risk of stroke

Stroke is one of the leading causes of disability worldwide. It places a huge burden on families, health systems and societies. Increasingly, strokes are not just occurring in older adults. They are affecting younger people ...

Recommended News For You

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

After cancer: Study explores caring-healing modalities for survivors

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

Recommended Articles For You

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals 

From Bench to Bedside: The New Era of Lymphoma Treatment and Education 

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes 

Liquid Biopsies in Hematology: A Window into the Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests

2.

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

3.

Prostate cancer explained: From antigen tests to treatment options

4.

Review looks at potential treatment targets in the tumor microenvironment.

5.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

1.

Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth 

2.

The benefits of using magnesium sulfate during pregnancy 

3.

Decoding Granular Cell Tumor: What You Need to Know

4.

Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results

5.

Revolutionizing Cancer Care with Fulphila: A New Hope for Patients

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

2.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

5.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot